Drug Patent Expirations in January 2014

Drug Patent Expirations for January 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
EPIVIR-HBV Glaxosmithkline lamivudine RE39155*PED Jan 2, 2014
MICARDIS Boehringer Ingelheim telmisartan 5,591,762 Jan 7, 2014
TWYNSTA Boehringer Ingelheim amlodipine besylate; telmisartan 5,591,762 Jan 7, 2014
COMBIPATCH Novartis estradiol; norethindrone acetate 6,024,976 Jan 7, 2014
GLUCOTROL XL Pfizer glipizide 5,591,454 Jan 7, 2014
VIVELLE-DOT Novartis estradiol 6,024,976 Jan 7, 2014
MICARDIS HCT Boehringer Ingelheim hydrochlorothiazide; telmisartan 5,591,762 Jan 7, 2014
RAPAMUNE Pf Prism Cv sirolimus 5,100,899*PED Jan 7, 2014
MINIVELLE Noven estradiol 6,024,976 Jan 7, 2014
ATACAND Astrazeneca candesartan cilexetil 5,534,534*PED Jan 9, 2014
ATACAND HCT Astrazeneca candesartan cilexetil; hydrochlorothiazide 5,534,534*PED Jan 9, 2014
PRECEDEX Hospira dexmedetomidine hydrochloride 4,910,214*PED Jan 15, 2014
SANDOSTATIN LAR Novartis octreotide acetate 5,538,739*PED Jan 23, 2014
XYZAL Ucb Inc levocetirizine dihydrochloride 5,698,558*PED Jan 26, 2014
DULERA Merck Sharp Dohme formoterol fumarate; mometasone furoate 6,677,323 Jan 27, 2014
NORVIR Abbott ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,635,523*PED Jan 30, 2014
KALETRA Abbvie lopinavir; ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,541,206*PED Jan 30, 2014
NORVIR Abbvie ritonavir 5,674,882*PED Jan 30, 2014
BETAXON Alcon Pharms Ltd levobetaxolol hydrochloride 5,540,918*PED Jan 30, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.

Contact Us with any questions.

Comments are closed.

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!